title: Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.
abstract: Ranibizumab (Lucentis(®)), an inhibitor of all vascular endothelial growth factor (VEGF) A isoforms, is approved for the intravitreal treatment of neovascular age-related macular degeneration (AMD). In pivotal trials, monthly injections of ranibizumab were superior to verteporfin photodynamic therapy in the treatment of predominantly classic choroidal neovascularization (CNV) due to neovascular AMD (ANCHOR) and sham in the treatment of minimally classic or occult CNV due to neovascular AMD (MARINA). Monthly or less frequent injections of ranibizumab are generally well tolerated and associated with low rates of ocular and systemic serious adverse events (SAEs). Less frequent dosing has been evaluated with the aim of reducing the burden, risk and cost of monthly injections. In the landmark CATT trial, monthly monitoring and retreatment as-needed with ranibizumab was equivalent to monthly treatment in terms of the vision gain at 1 year, but reduced the number of injections (and the related cost) by approximately one-half. In head-to-head comparisons, aflibercept administered bimonthly was noninferior to ranibizumab administered monthly (VIEW 1 and 2), bevacizumab administered monthly was equivalent to ranibizumab administered monthly (CATT), and bevacizumab administered as-needed was equivalent to ranibizumab administered as-needed (CATT). Bevacizumab is widely used (off-label) for economic reasons; while it was less costly than ranibizumab, it was associated with more systemic SAEs. Notwithstanding the availability of other similarly effective anti-VEGF therapies that are approved (aflibercept) or unapproved (bevacizumab), ranibizumab continues to set the standard as regards the totality of evidence from randomized clinical trials demonstrating its efficacy and tolerability (particularly that of the monthly regimen) in the treatment of neovascular AMD.
authors.affiliation: Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@springer.com
authors.forename: James E
authors.initials: JE
authors.lastname: Frampton
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000191:economics / Q000627:therapeutic use*; D020256:Choroidal Neovascularization / Q000188:drug therapy; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005060:Europe; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D016896:Treatment Outcome; D014481:United States; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab
references.citation: Curr Vasc Pharmacol. 2011 Sep;9(5):629-46
references.pmid: 21470108
references.citation: Arch Ophthalmol. 2010 Dec;128(12):1523-7
references.pmid: 21149773
references.citation: Graefes Arch Clin Exp Ophthalmol. 2008 Nov;246(11):1527-34
references.pmid: 18642019
references.citation: Br J Ophthalmol. 2012 Dec;96(12):1469-73
references.pmid: 23001255
references.citation: N Engl J Med. 2006 Oct 5;355(14):1419-31
references.pmid: 17021318
references.citation: Ophthalmology. 2012 May;119(5):1001-10
references.pmid: 22444829
references.citation: Biochem Biophys Res Commun. 2011 May 6;408(2):276-81
references.pmid: 21501594
references.citation: Ophthalmology. 2009 Sep;116(9):1731-9
references.pmid: 19643495
references.citation: Drugs Aging. 2009;26(4):295-320
references.pmid: 19476398
references.citation: Am J Ophthalmol. 2011 May;151(5):887-895.e1
references.pmid: 21310390
references.citation: Am J Ophthalmol. 2012 Oct;154(4):682-686.e2
references.pmid: 22818800
references.citation: Graefes Arch Clin Exp Ophthalmol. 2006 Sep;244(9):1132-42
references.pmid: 16538452
references.citation: Acta Ophthalmol. 2012 Feb;90(1):e25-30
references.pmid: 21958440
references.citation: Mayo Clin Proc. 2012 Jan;87(1):77-88
references.pmid: 22212972
references.citation: Curr Opin Ophthalmol. 2012 May;23(3):182-8
references.pmid: 22450218
references.citation: Clin Sci (Lond). 2005 Sep;109(3):227-41
references.pmid: 16104843
references.citation: Arch Ophthalmol. 2009 Jan;127(1):13-21
references.pmid: 19139332
references.citation: Drugs Aging. 2011 Nov 1;28(11):853-65
references.pmid: 21970950
references.citation: Expert Opin Drug Saf. 2010 Jan;9(1):149-65
references.pmid: 20001757
references.citation: Ophthalmology. 2012 Jul;119(7):1388-98
references.pmid: 22555112
references.citation: Retina. 2012 Feb;32(2):293-8
references.pmid: 21926941
references.citation: Ophthalmology. 2007 Oct;114(10):1868-75
references.pmid: 17628683
references.citation: Ann Pharmacother. 2012 Feb;46(2):290-6
references.pmid: 22274144
references.citation: Br Med Bull. 2008;85:127-49
references.pmid: 18334518
references.citation: Ophthalmology. 2013 Jan;120(1):130-9
references.pmid: 23021093
references.citation: Angiogenesis. 2012 Jun;15(2):171-85
references.pmid: 22302382
references.citation: Am J Ophthalmol. 2008 May;145(5):862-74
references.pmid: 18321465
references.citation: Ophthalmology. 2009 Jan;116(1):57-65.e5
references.pmid: 19118696
references.citation: Eur J Ophthalmol. 2010 Jan-Feb;20(1):174-9
references.pmid: 19927267
references.citation: Clin Ther. 2008 Dec;30(12):2436-51
references.pmid: 19167602
references.citation: N Engl J Med. 2006 Oct 5;355(14):1474-85
references.pmid: 17021323
references.citation: N Engl J Med. 2010 Oct 21;363(17):1648-55
references.pmid: 20961248
references.citation: Am J Ophthalmol. 2007 Apr;143(4):566-83
references.pmid: 17386270
references.citation: Br J Ophthalmol. 2008 Apr;92(4):584
references.pmid: 18369083
references.citation: Cost Eff Resour Alloc. 2008 Jun 24;6:12
references.pmid: 18573218
references.citation: Br J Ophthalmol. 2010 Jan;94(1):2-13
references.pmid: 19443462
references.citation: J Ophthalmol. 2012;2012:786870
references.pmid: 22523653
references.citation: J Ophthalmol. 2011;2011:405724
references.pmid: 22174994
references.citation: Expert Opin Biol Ther. 2012 Mar;12(3):371-81
references.pmid: 22309606
references.citation: Ophthalmology. 2010 Nov;117(11):2134-40
references.pmid: 20591490
references.citation: Ophthalmology. 2013 Jan;120(1):160-8
references.pmid: 23009891
references.citation: Retina. 2011 Jan;31(1):26-30
references.pmid: 20890246
references.citation: Exp Eye Res. 2007 Oct;85(4):425-30
references.pmid: 17714704
references.citation: Am J Ophthalmol. 2009 Jul;148(1):43-58.e1
references.pmid: 19376495
references.citation: Am J Ophthalmol. 2007 Apr;143(4):679-80
references.pmid: 17386275
references.citation: Ophthalmology. 2008 Jun;115(6):1039-1045.e5
references.pmid: 17976724
references.citation: Ophthalmology. 2012 Dec;119(12):2537-48
references.pmid: 23084240
references.citation: Drugs. 2012 Mar 5;72(4):509-23
references.pmid: 22356289
references.citation: Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005139
references.pmid: 18425911
references.citation: Can J Ophthalmol. 2010 Dec;45(6):590-5
references.pmid: 21135894
references.citation: Br J Ophthalmol. 2010 Mar;94(3):292-6
references.pmid: 19951942
references.citation: Drugs. 2007;67(8):1199-206; discussion 1207-9
references.pmid: 17521219
references.citation: Am J Ophthalmol. 2009 May;147(5):831-7
references.pmid: 19217019
references.citation: Retina. 2010 Oct;30(9):1390-9
references.pmid: 20924261
references.citation: N Engl J Med. 2006 Oct 5;355(14):1432-44
references.pmid: 17021319
references.citation: Health Technol Assess. 2008 May;12(16):iii-iv, ix-201
references.pmid: 18462575
references.citation: Adv Exp Med Biol. 2012;724:15-36
references.pmid: 22411231
references.citation: Graefes Arch Clin Exp Ophthalmol. 2010 Apr;248(4):467-76
references.pmid: 19669678
references.citation: Retina. 2009 Mar;29(3):313-8
references.pmid: 19287287
references.citation: Ophthalmology. 2011 Apr;118(4):663-71
references.pmid: 21459217
references.citation: Drugs Aging. 2007;24(8):643-62
references.pmid: 17702534
references.citation: Am J Ophthalmol. 2010 Sep;150(3):315-324.e1
references.pmid: 20598667
references.citation: Can J Ophthalmol. 2012 Jun;47(3):275-9
references.pmid: 22687306
references.citation: Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4523-7
references.pmid: 18441313
references.citation: Retina. 2008 Nov-Dec;28(10):1395-9
references.pmid: 18827737
references.citation: Clin Ther. 2010 Jul;32(7):1343-56
references.pmid: 20678682
references.citation: Ophthalmology. 2011 Dec;118(12):2447-52
references.pmid: 21872935
references.citation: Arch Ophthalmol. 2011 Jun;129(6):709-17
references.pmid: 21670337
references.citation: Br J Ophthalmol. 2007 Sep;91(9):1244-6
references.pmid: 17431015
references.citation: Retina. 2010 Oct;30(9):1376-85
references.pmid: 20683380
references.citation: Drugs Aging. 2012 Oct;29(10):839-46
references.pmid: 23038609
references.citation: Ophthalmology. 2011 May;118(5):831-9
references.pmid: 21146229
references.citation: Nat Med. 2003 Jun;9(6):669-76
references.pmid: 12778165
references.citation: Br J Ophthalmol. 2006 Dec;90(12):1542-7
references.pmid: 17114590
references.citation: Arch Ophthalmol. 2007 Nov;125(11):1460-9
references.pmid: 17998507
references.citation: Ophthalmology. 2011 Oct;118(10):2028-34
references.pmid: 21705087
references.citation: Exp Eye Res. 2009 Mar;88(3):522-7
references.pmid: 19135441
references.citation: N Engl J Med. 2011 May 19;364(20):1897-908
references.pmid: 21526923
references.citation: Graefes Arch Clin Exp Ophthalmol. 2012 Nov;250(11):1563-71
references.pmid: 23011000
references.citation: J Cell Biochem. 2009 Dec 15;108(6):1410-7
references.pmid: 19859900
references.citation: Clin Ther. 2012 Feb;34(2):446-56
references.pmid: 22289279
references.citation: Br J Ophthalmol. 2011 Apr;95(4):530-3
references.pmid: 20937739
references.citation: J Vis Impair Blind. 2008;102(10):591-599
references.pmid: 20011131
references.citation: Ophthalmology. 2012 May;119(5):992-1000
references.pmid: 22424834
references.citation: Ophthalmology. 2012 Oct;119(10):2082-6
references.pmid: 22920670
references.citation: Retina. 2012 Oct;32(9):1821-8
references.pmid: 23011184
references.citation: Am J Ophthalmol. 2007 Dec;144(6):850-857
references.pmid: 17949673
references.citation: Int J Nanomedicine. 2006;1(3):263-8
references.pmid: 17717967
references.citation: Surv Ophthalmol. 1995 Mar-Apr;39(5):367-74
references.pmid: 7604360
references.citation: N Engl J Med. 2004 Dec 30;351(27):2805-16
references.pmid: 15625332
references.citation: Ophthalmology. 2012 Jul;119(7):1399-411
references.pmid: 22578446
references.citation: Drugs. 2008;68(8):1029-36
references.pmid: 18484796
references.citation: Am J Ophthalmol. 2008 Feb;145(2):239-248
references.pmid: 18222192
references.citation: Ophthalmology. 2012 Jun;119(6):1175-83
references.pmid: 22306121
references.citation: Arch Ophthalmol. 2006 Nov;124(11):1532-42
references.pmid: 17101999
references.citation: J Eval Clin Pract. 2012 Apr;18(2):247-55
references.pmid: 20846318
references.citation: Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):639-44
references.pmid: 20890777
references.citation: Pharmacoeconomics. 2011 Feb;29(2):107-31
references.pmid: 21244102
references.citation: Ophthalmology. 2007 Feb;114(2):246-52
references.pmid: 17270674
references.citation: Retina. 2006 Oct;26(8):859-70
references.pmid: 17031284
references.citation: Retina. 2012 Sep;32(8):1453-64
references.pmid: 22426346
references.citation: Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1837-42
references.pmid: 17347807
references.citation: Am J Ophthalmol. 2013 Jan;155(1):89-95.e3
references.pmid: 23022167